Scientists produce nanoscale droplets with cancer-fighting implications
UCLA scientists have succeeded in making unique nanoscale droplets that are much smaller than human cells and can potentially be used to deliver pharmaceuticals.
“What we found that was unexpected was within each oil droplet there was also a water droplet — a double emulsion,” said Timothy Deming, professor and chair of the UCLA Department of Bioengineering and a member of both the California NanoSystems Institute (CNSI) at UCLA and UCLA’s Jonsson Cancer Center. “We have a water droplet inside of an oil droplet, in water.”
The big challenge,” Deming added, “was to make these double-emulsion droplets in the sub-100nm size range with these properties and have them be stable. We have demonstrated we can make these emulsions that are stable in this size range, which no one has ever been able to do before. These double nanoemulsions are generally hard to form and very unstable, but ours are very stable.”
Emulsions are droplets of one liquid in another liquid; the two liquids do not mix.
“This gives us a new tool, a new material, for drug delivery and anticancer applications,” said Thomas G. Mason, a UCLA associate professor of chemistry and physics who has been leading research on nanoemulsions since he joined UCLA five years ago. Mason, who holds UCLA’s John McTague Career Development Chair, is also a member of the CNSI.
Deming and Mason have made nanoemulsions containing billions of double nanodroplets. Their research, reporting on droplets smaller than 100nm — the world’s smallest double emulsions — appears in the Sept. 4 edition of the journal Nature.
“If we have water-soluble drugs, we can load them inside,” Deming said. “If we have water-insoluble drugs, we can load them inside as well. We can deliver them simultaneously.”
“Here, you effectively combine both types of drug molecules in the same delivery package,” Mason said. “This approach could be used for a combination therapy where you want to deliver two drugs simultaneously at a fixed ratio into the same location.”
It might be possible, the scientists said, to insert a pharmaceutical inside a droplet and inject the droplet inside a cell to release its cargo. For example, one approach might involve an anticancer drug in the oil and a toxin-protein in the water — two molecules trying to kill the cell simultaneously. While a cell can develop resistance to a single drug, the combination approach can be more effective, the scientists said.
Deming, who designs and engineers molecules, noted that “there are still challenges for drug delivery, but we have demonstrated the key first step, that we can make these double emulsions that are stable in this size range.”
Deming and Mason caution that while this approach holds promise for fighting cancer, there are still many steps, and likely many years of research, before patients could be treated in this way. Clinical trials using this research would probably be years off.
“We’ll have to do a lot of fine-tuning, but this approach has a lot of advantages,” Deming said. “The size of these is a big advantage. We have discovered unique molecular features that can stabilize double emulsions. These are promising, but it’s early on, and there are many ways these can fail. But we should at least learn how to make better drug-delivery vehicles.”
In future research, Deming and Mason want to make sure the droplets can harmlessly enter cells and release their cargo.
NanoPacific Holdings Inc. has licensed this nanodroplet technology from UCLA to develop and commercialize the technology in a variety of applications.